Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus PT from Analysts

Aura Biosciences, Inc. (NASDAQ:AURAGet Free Report) has been assigned an average rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $23.00.

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. BTIG Research raised their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, Scotiabank lifted their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th.

Get Our Latest Stock Analysis on Aura Biosciences

Insider Transactions at Aura Biosciences

In other news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,778 shares of company stock worth $240,706 over the last three months. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after acquiring an additional 3,612 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after purchasing an additional 8,194 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at about $87,000. Renaissance Technologies LLC increased its position in Aura Biosciences by 26.3% during the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after buying an additional 15,000 shares during the period. Finally, American Century Companies Inc. acquired a new position in Aura Biosciences during the second quarter worth approximately $119,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 1.8 %

Shares of Aura Biosciences stock opened at $7.85 on Friday. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The company has a market cap of $392.11 million, a P/E ratio of -4.54 and a beta of 0.30. The company’s fifty day simple moving average is $8.33 and its two-hundred day simple moving average is $8.92.

Aura Biosciences (NASDAQ:AURAGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Analysts predict that Aura Biosciences will post -1.67 EPS for the current fiscal year.

Aura Biosciences Company Profile

(Get Free Report

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

See Also

Analyst Recommendations for Aura Biosciences (NASDAQ:AURA)

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.